IL2 and pancreatic neoplasm: We then chose to deploy this IL-2 circuit in targeting the mouse pancreatic tumor model KPC (KrasLSL.G12D/+; p53R172H/+; PdxCretg/+) (31, 32), as this immune-excluded tumor exhibits the challenging immunotherapy refractory features of pancreatic ductal adenocarcinoma (PDAC) (33).